BACKGROUND: Pneumocystis jirovecii, formerly carinii, pneumonia (PCP) poses a life-threatening risk to oncology patients. The use of trimethoprim-sulfamethoxazole (TMP-SMZ) prophylaxis virtually eliminates the risk of infection; however, many patients cannot tolerate TMP-SMZ. We performed a retrospective analysis to determine the PCP breakthrough rate in pediatric oncology patients receiving intravenous pentamidine as second line PCP prophylaxis. PROCEDURE: We conducted a retrospective chart review of pediatric oncology patients who received intravenous pentamidine from 2001 to 2006 at our institution. The diagnosis, age and bone marrow transplant (BMT) status were determined. A subset of patients had review of their records to determine the justification for discontinuing TMP-SMZ. Children who developed symptoms of pneumonia with a clinical suspicion of PCP underwent bronchoscopy, allowing for identification of Pneumocystis. RESULTS: A total of 232 patients received 1,706 doses of intravenous pentamidine and no toxicities were identified. The main reasons for discontinuing TMP-SMZ were bone marrow suppression and drug allergy. Three children developed PCP, equating to a breakthrough rate of 1.3%. Two of these children had undergone BMT (1.9% breakthrough rate) and both were under the age of two (6.5% breakthrough rate). CONCLUSIONS: The use of intravenous pentamidine as PCP prophylaxis results in a breakthrough rate of 1.3%. TMP-SMZ is the first choice for PCP prophylaxis. However, when necessary, the use of intravenous pentamidine has an acceptably low failure rate, even in high-risk BMT patients. Other options should be considered for children less than 2 years of age. (c) 2008 Wiley-Liss, Inc.
BACKGROUND:Pneumocystis jirovecii, formerly carinii, pneumonia (PCP) poses a life-threatening risk to oncology patients. The use of trimethoprim-sulfamethoxazole (TMP-SMZ) prophylaxis virtually eliminates the risk of infection; however, many patients cannot tolerate TMP-SMZ. We performed a retrospective analysis to determine the PCP breakthrough rate in pediatric oncology patients receiving intravenous pentamidine as second line PCP prophylaxis. PROCEDURE: We conducted a retrospective chart review of pediatric oncology patients who received intravenous pentamidine from 2001 to 2006 at our institution. The diagnosis, age and bone marrow transplant (BMT) status were determined. A subset of patients had review of their records to determine the justification for discontinuing TMP-SMZ. Children who developed symptoms of pneumonia with a clinical suspicion of PCP underwent bronchoscopy, allowing for identification of Pneumocystis. RESULTS: A total of 232 patients received 1,706 doses of intravenous pentamidine and no toxicities were identified. The main reasons for discontinuing TMP-SMZ were bone marrow suppression and drug allergy. Three children developed PCP, equating to a breakthrough rate of 1.3%. Two of these children had undergone BMT (1.9% breakthrough rate) and both were under the age of two (6.5% breakthrough rate). CONCLUSIONS: The use of intravenous pentamidine as PCP prophylaxis results in a breakthrough rate of 1.3%. TMP-SMZ is the first choice for PCP prophylaxis. However, when necessary, the use of intravenous pentamidine has an acceptably low failure rate, even in high-risk BMT patients. Other options should be considered for children less than 2 years of age. (c) 2008 Wiley-Liss, Inc.
Authors: M J Lim; A Stebbings; S J Lim; K Foor; J-Z Hou; R Farah; A Raptis; S Marks; D Weber; A Im; K Dorritie; A Sehgal; M Agha; S H Lim Journal: Bone Marrow Transplant Date: 2015-06-08 Impact factor: 5.483
Authors: George K Siberry; Mark J Abzug; Sharon Nachman; Michael T Brady; Kenneth L Dominguez; Edward Handelsman; Lynne M Mofenson; Steve Nesheim Journal: Pediatr Infect Dis J Date: 2013-11 Impact factor: 2.129
Authors: D A Curi; R E Duerst; C Badke; J Bell; S Chaudhury; M Kletzel; J Schneiderman; W T Tse; W J Muller; N Hijiya Journal: Bone Marrow Transplant Date: 2016-05-23 Impact factor: 5.483
Authors: Adam J Esbenshade; Richard H Ho; Ayumi Shintani; Zhiguo Zhao; Lesley-Ann Smith; Debra L Friedman Journal: Cancer Date: 2011-01-18 Impact factor: 6.860
Authors: Melissa Quinn; J T Fannin; Joseph Sciasci; Allison Bragg; Patrick K Campbell; Delia Carias; Kristine R Crews; David Gregornik; Sima Jeha; Gabriela Maron; Jennifer L Pauley; Hope D Swanson; Joshua Wolf; William Greene Journal: Antimicrob Agents Chemother Date: 2018-07-27 Impact factor: 5.191
Authors: K M Williams; K W Ahn; M Chen; M D Aljurf; A L Agwu; A R Chen; T J Walsh; P Szabolcs; M J Boeckh; J J Auletta; C A Lindemans; J Zanis-Neto; M Malvezzi; J Lister; J S de Toledo Codina; K Sackey; J L H Chakrabarty; P Ljungman; J R Wingard; M D Seftel; S Seo; G A Hale; B Wirk; M S Smith; B N Savani; H M Lazarus; D I Marks; C Ustun; H Abdel-Azim; C C Dvorak; J Szer; J Storek; A Yong; M R Riches Journal: Bone Marrow Transplant Date: 2016-01-04 Impact factor: 5.483